List of Excipients in Branded Drug VISTIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	VISTIDE	cidofovir	61958-0101	HYDROCHLORIC ACID
Gilead Sciences Inc	VISTIDE	cidofovir	61958-0101	SODIUM HYDROXIDE
Gilead Sciences Inc	VISTIDE	cidofovir	61958-0101	WATER

VISTIDE Excipient Strategy and Commercial Opportunities for Cidofovir

Last updated: August 9, 2026

VISTIDE is an injectable cidofovir product whose commercial value is constrained by nephrotoxicity, intravenous administration, probenecid coadministration, hydration requirements, limited CMV use, and the availability of generic cidofovir injection. The clearest excipient opportunities are not simple preservative or buffer substitutions. They are ready-to-use presentations, improved dilution stability, reduced administration burden, pediatric dosing, container-closure optimization, and delivery systems that preserve renal safety.

What is VISTIDE and how is it formulated?

VISTIDE is cidofovir injection, an antiviral nucleotide phosphonate approved for the treatment of cytomegalovirus retinitis in patients with AIDS and without adequate renal function impairment. The product is administered intravenously after dilution and requires probenecid and intravenous saline hydration to reduce renal toxicity.[1]

VISTIDE composition and administration

Attribute	VISTIDE profile
Active ingredient	Cidofovir
Dosage form	Sterile aqueous concentrate for intravenous infusion
Strength	75 mg/mL
Packaged dose	375 mg in 5 mL
Primary excipients	Sodium hydroxide and water for injection
Preservative	None
Administration	Dilution in 100 mL of 0.9% sodium chloride and intravenous infusion over one hour
Supportive therapy	Probenecid and intravenous saline hydration
Key formulation issue	Renal toxicity and administration complexity
Original sponsor	Gilead Sciences
FDA approval	1996

The formulation is intentionally simple. Sodium hydroxide adjusts pH, while water for injection provides the vehicle. The product does not rely on a complex buffer system, surfactant package, preservative, or organic cosolvent.[1]

Cidofovir is highly polar and has limited membrane permeability. Its formulation challenge is therefore different from that of poorly water-soluble small molecules. Solubility is not the primary commercial problem. Renal exposure, infusion logistics, chemical stability, and patient handling are more important.

What excipients are used in VISTIDE?

VISTIDE uses sodium hydroxide and water for injection as inactive ingredients. The label identifies the product as a preservative-free aqueous concentrate with a pH of approximately 7.4.[1]

Why the original excipient system matters

The minimal excipient system creates both advantages and limitations:

• It reduces the risk of excipient-related hypersensitivity.
• It supports a straightforward sterile manufacturing process.
• It avoids preservative exposure in an immunocompromised population.
• It leaves limited room for differentiation through conventional excipient replacement.
• It does not solve the requirement for dilution, saline hydration, or probenecid.
• It provides little formulation-based protection against cidofovir’s renal toxicity.

Any reformulation must preserve cidofovir stability, sterility, compatibility with infusion materials, and acceptable osmolality. A new excipient cannot be promoted as nephroprotective without clinical evidence. Renal risk is primarily linked to cidofovir exposure and proximal tubular toxicity, while probenecid and hydration are part of the approved risk-management regimen.[1,2]

What excipient strategies could improve VISTIDE?

The strongest strategy is to reduce operational burden without making unsupported claims that the formulation changes cidofovir’s intrinsic renal toxicity.

Ready-to-use or pharmacy-ready presentations

The current product requires preparation before infusion. A commercial reformulation could provide:

• A ready-to-use 100 mL infusion bag.
• A pharmacy-ready vial with a calibrated dilution system.
• A dual-chamber container separating cidofovir concentrate from saline.
• A premeasured low-volume presentation for weight-based dosing.
• A closed-system transfer device that reduces manipulation.

A ready-to-use product could reduce compounding errors, shorten pharmacy preparation time, and improve outpatient or ambulatory infusion workflows. The main development issues would be long-term stability in the final container, extractables and leachables, container compatibility, and microbial control.

A premixed presentation would likely require a new drug application pathway rather than a conventional ANDA if the formulation, container, or administration configuration creates material differences from the reference product.

Buffer and pH optimization

Sodium hydroxide is used to adjust pH. A reformulator could investigate phosphate, citrate, acetate, or other buffer systems, but the commercial value would depend on a demonstrated advantage.

Potential objectives include:

• Improved long-term pH control.
• Reduced degradation during refrigerated storage.
• Greater stability after dilution.
• Lower interaction with infusion bags or administration sets.
• Better compatibility with alternative container materials.

Buffer selection requires careful assessment. Phosphate and citrate can affect metal-ion interactions, precipitation, osmolality, and compatibility with sterilization conditions. A buffer that improves chemical stability in the vial may reduce stability after dilution or increase incompatibility with saline-based infusion systems.

The most defensible patent position would require an unexpected stability or compatibility result rather than a routine selection of a pharmaceutically acceptable buffer.

Chelators and metal-ion control

A chelating excipient such as edetate could be evaluated to control trace-metal catalyzed degradation. This strategy is technically plausible for an aqueous injectable but would require evidence that:

1. Trace metals contribute materially to degradation.
2. The chelator improves shelf life or diluted-solution stability.
3. The chelator does not create toxicity, compatibility, or regulatory problems.
4. The effect is reproducible across manufacturing lots and container systems.

A chelator could support composition, stability, and manufacturing-process claims. It would not automatically support a renal-safety claim.

Surfactants and protein-based stabilizers

Surfactants such as polysorbates or poloxamers are unlikely to provide a first-line commercial advantage for VISTIDE because cidofovir is not primarily limited by interfacial aggregation or poor aqueous solubility. Their use could increase analytical and regulatory complexity.

Potential justifications would include prevention of adsorption to infusion materials or improved stability in a novel delivery system. A surfactant strategy would need to address peroxide impurities, oxidation, particulate formation, and compatibility with parenteral administration.

Preservative-free multidose alternatives

A multidose preserved VISTIDE product is commercially less attractive than a single-use sterile presentation. The target population is immunocompromised, and the existing product is preservative-free. A preservative could create safety concerns and would not address the central administration burden.

The stronger opportunity is a unit-dose, preservative-free container with improved handling and reduced preparation steps.

Lyophilized or solid-state presentations

A lyophilized cidofovir product could improve storage stability and permit reconstitution immediately before use. The disadvantages include:

• More complex manufacturing.
• Reconstitution time.
• Risk of operator error.
• Need to demonstrate complete dissolution.
• Potentially higher cost.
• No inherent reduction in renal toxicity or infusion time.

Lyophilization could become commercially relevant if it materially extends shelf life, enables room-temperature distribution, or supports a smaller package. It is less compelling if the existing aqueous concentrate already has adequate stability and cold-chain logistics are manageable.

What formulations are protected by VISTIDE-related patents?

The original VISTIDE intellectual-property position centered on cidofovir and its antiviral use rather than a broad, modern excipient platform. Core compound and early use patents are generally old relative to the 1996 approval date and are unlikely to create a durable barrier to a new cidofovir injection by themselves.

Potential formulation patent claim categories

A new sponsor could pursue claims covering:

Claim category	Possible subject matter	Commercial strength
Composition	Cidofovir with a defined buffer, pH range, chelator, or stabilizer	Moderate if unexpected stability is shown
Concentration	High- or low-concentration aqueous cidofovir	Low to moderate unless linked to a technical effect
Diluted product	Cidofovir in saline with defined hold time and degradation limits	Moderate
Container	Specific bag, vial, syringe, or polymer composition	Moderate
Container closure	Low-sorption or low-leachables system	Moderate
Manufacturing	Sterilization, filtration, nitrogen overlay, or oxygen-control process	Moderate
Administration system	Dual-chamber device or closed transfer configuration	Moderate to strong
Method of use	Reduced preparation burden or modified dosing regimen	Variable and dependent on clinical support
Delivery technology	Lipid, nanoparticle, depot, or targeted renal-sparing system	Potentially strong but high risk

Formulation patents should be drafted around measurable technical results. Broad claims covering “cidofovir and a pharmaceutically acceptable excipient” would face substantial obviousness risk because sterile aqueous formulations, pH adjustment, buffers, chelators, and standard container systems are familiar pharmaceutical techniques.

When does VISTIDE lose exclusivity?

VISTIDE’s original small-molecule and early-use exclusivity has expired. The FDA approved VISTIDE in 1996, and any original patent term associated with early cidofovir discoveries would ordinarily have ended by the late 2000s or early 2010s, subject to patent-term adjustment, patent-term extension, and pediatric exclusivity.[1,3]

Exclusivity timeline

Event	Approximate timing
FDA approval of VISTIDE	1996
Original compound patent era	Late 1980s to early 1990s filings
Typical unadjusted 20-year patent expiration	Late 2000s to early 2010s
Likely original regulatory exclusivity window	Expired
Current competitive issue	Generic or alternative cidofovir injection, supply, and formulation differentiation

The relevant commercial question is therefore not whether the original VISTIDE molecule remains protected. It is whether any current, unexpired patent covers a specific formulation, manufacturing process, device, or method of use. A sponsor launching a new cidofovir product must review the current FDA Orange Book, patent certifications, FDA product-status records, and applicable court proceedings before setting a launch date.[3,4]

What is the Orange Book status of VISTIDE?

VISTIDE is a small-molecule drug product, so generic competition would proceed through the ANDA pathway rather than the biosimilar pathway. The Orange Book analysis depends on the current reference-listed-drug designation, marketing status, listed patents, and any regulatory exclusivity associated with the product.[3]

Paragraph IV risk

A generic applicant could file an ANDA with a Paragraph IV certification against any listed patent that it believes is invalid, unenforceable, or not infringed. The main potential targets would be:

• Product composition claims.
• Concentration or pH claims.
• Stability claims.
• Container or administration claims.
• Method-of-use claims directed to CMV retinitis.

If no unexpired patent is listed, the principal barrier becomes regulatory and commercial rather than patent-based. If a new formulation patent is listed, a Paragraph IV notice could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[5]

Generic entry risks

Generic cidofovir faces several practical barriers even after patent expiry:

• Limited market size.
• Complex handling requirements.
• Renal monitoring and probenecid use.
• Potentially weak return on sterile manufacturing investment.
• Low-volume demand relative to common antivirals.
• Product-supply and procurement requirements.
• Need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

These factors can delay entry without creating legal exclusivity. A thin generic field can support pricing stability, but it does not provide the same protection as a valid patent.

Is there biosimilar risk for VISTIDE?

No. Cidofovir is a chemically synthesized small molecule, not a biologic. VISTIDE is exposed to generic-drug risk, not biosimilar substitution under the Public Health Service Act.[5]

The relevant competitive products are:

• Generic cidofovir injection.
• Compounded cidofovir preparations, where legally permitted.
• Alternative anti-CMV therapies.
• Investigational or off-label antiviral regimens.
• New cidofovir delivery systems.

A reformulated cidofovir product could use a 505(b)(2) application if it relies in part on FDA findings for the existing product while introducing a new formulation, dosage form, route, or administration configuration.[6]

What FDA regulatory pathway applies to a new VISTIDE formulation?

The pathway depends on the degree of change from the reference product.

ANDA

An ANDA is most suitable for a product that is pharmaceutically equivalent to the reference drug and satisfies applicable bioequivalence and quality requirements. Excipients may differ within FDA-accepted limits, but a materially different formulation, container, concentration, or administration method can create regulatory complexity.

505(b)(2) application

A 505(b)(2) application is more suitable for:

• A ready-to-use infusion product.
• A new concentration.
• A new container or delivery device.
• A lyophilized formulation.
• A novel excipient combination.
• A modified administration regimen.
• A product supported by published data or prior FDA findings for cidofovir.

A 505(b)(2) applicant may obtain patent protection for the new formulation or method, but the scope of protection will depend on the claims and the FDA-approved labeling.

Compounded product

Compounding may address limited clinical demand but is a weak platform for a branded commercial strategy. Compounded products generally lack the same premarket review, manufacturing consistency, labeling control, and patent-protection opportunities as an approved product.

How strong is the patent estate for a new VISTIDE excipient product?

The patent estate for the original VISTIDE product is weak as a current exclusivity platform because the product has been marketed for decades. The patent estate for a technically differentiated reformulation could be moderate if it produces measurable advantages.

Stronger patent concepts

The strongest opportunities are likely to involve:

• A defined excipient combination that extends diluted-solution stability.
• A container system that minimizes cidofovir adsorption or leachables.
• A ready-to-use formulation with validated shelf life.
• A dual-chamber system that combines cidofovir and saline at administration.
• A low-volume presentation that preserves dosing accuracy.
• A formulation compatible with a clinically meaningful alternative infusion workflow.

Weaker patent concepts

The following concepts are more vulnerable to obviousness challenges:

• Replacing sodium hydroxide with another routine pH adjuster.
• Adding a conventional buffer without an unexpected result.
• Using standard sterile water, saline, or commonly used surfactants.
• Changing vial size without a technical advantage.
• Claiming a broad range of routine pH values.
• Claiming a standard lyophilization cycle without a formulation-specific benefit.

A commercially useful patent program should combine composition claims with process, container, device, and method-of-use claims. This layered strategy is more resilient than relying on a single excipient claim.

What commercial opportunities exist for VISTIDE reformulation?

Hospital and ambulatory infusion efficiency

The most immediate opportunity is reducing pharmacy preparation and infusion-center handling. A ready-to-use or simplified dilution product could generate value through labor savings and lower preparation risk even if the active ingredient remains unchanged.

Pediatric and weight-based dosing

Cidofovir use outside the original adult AIDS population may create demand for dose-flexible presentations. Smaller vials, prefilled syringes for controlled preparation, or calibrated dilution devices could support weight-based dosing. These products would require careful control of dosing accuracy and sterile handling.

Supply-chain differentiation

A room-temperature-stable or less cold-chain-dependent product could improve distribution economics. The value would depend on demonstrated shelf-life extension, not on packaging claims alone.

Global and emerging-market supply

Many markets have limited access to specialized anti-CMV therapy. A lower-cost generic injection may have more commercial potential than a premium reformulation. A differentiated excipient or container system must therefore justify its price through reduced waste, easier preparation, broader storage conditions, or improved availability.

Licensing opportunities

The most attractive licensing targets are likely to include:

• Sterile ready-to-use infusion technologies.
• Dual-chamber bags and reconstitution devices.
• Low-sorption polymer containers.
• Stabilization platforms for aqueous phosphonate drugs.
• Renal-targeted or controlled-release delivery technologies.
• Contract manufacturing capacity for low-volume sterile injectables.

Licensing a platform technology can reduce development time, but the sponsor must confirm that the platform works with cidofovir’s high polarity, aqueous environment, required dose, and infusion conditions.

How does VISTIDE compare with competing CMV therapies?

Product or class	Administration	Main commercial advantage	Main limitation
Cidofovir	Intravenous	Useful antiviral option for selected CMV cases	Nephrotoxicity, probenecid, hydration, infusion
Ganciclovir	Intravenous or oral prodrug depending on product	Established CMV treatment platform	Myelosuppression and resistance concerns
Valganciclovir	Oral	Avoids routine intravenous infusion	Hematologic toxicity and oral absorption considerations
Foscarnet	Intravenous	Alternative for resistant CMV	Nephrotoxicity and electrolyte disorders
Maribavir	Oral	Oral treatment for refractory or resistant CMV	Different clinical positioning and market access considerations

Cidofovir’s reformulation opportunity is therefore tied to patients for whom existing oral or intravenous alternatives are unsuitable. A new excipient system that does not reduce administration burden or improve stability would face limited willingness to pay.

What patent litigation and settlement issues affect VISTIDE?

No current high-value VISTIDE patent dispute is central to the commercial outlook based on the product’s age and the expiration of its original patent era. The litigation risk for a new product would arise from later formulation, device, manufacturing, or method patents rather than from the original cidofovir molecule.

A Paragraph IV dispute could occur if a sponsor obtains and lists a valid patent covering a new VISTIDE-related presentation. Settlement terms could include delayed entry, authorized generic rights, licensing, or geographic restrictions. Those terms would materially affect market entry and should be evaluated against the limited size of the CMV cidofovir market.

Key Takeaways

• VISTIDE is a preservative-free aqueous cidofovir concentrate containing sodium hydroxide and water for injection.
• The main commercial weakness is administration complexity, not poor solubility.
• The best excipient opportunities involve stability, compatibility, ready-to-use delivery, and reduced pharmacy handling.
• A simple buffer or pH substitution is unlikely to support a strong patent position without unexpected technical results.
• Cidofovir is subject to generic-drug risk, not biosimilar risk.
• Original VISTIDE compound and early-use exclusivity have expired.
• A new formulation would likely require an ANDA or 505(b)(2) analysis depending on the degree of product change.
• The strongest patent estate would combine formulation, container, device, manufacturing, and method-of-use claims.
• The commercial opportunity is niche and depends on reducing total treatment burden rather than merely changing inactive ingredients.

FAQs

Can a new excipient reduce cidofovir nephrotoxicity?

Not on formulation rationale alone. A credible nephrotoxicity claim would require pharmacokinetic, toxicology, and clinical evidence showing reduced renal exposure or injury.

Could VISTIDE be reformulated as an oral product?

An oral product would be a major delivery-system project because cidofovir is highly polar and has limited oral permeability. It would likely require a prodrug, absorption-enhancing system, carrier, or targeted delivery technology rather than conventional excipient substitution.

Is a premixed cidofovir infusion likely to receive new patent protection?

It could, if the product has a novel container, validated stability profile, or administration system that is not obvious from existing sterile-infusion practice. Broad claims to cidofovir in saline would be more vulnerable.

Does probenecid qualify as part of the VISTIDE formulation strategy?

No. Probenecid is coadministered supportive therapy, not an inactive ingredient in the VISTIDE vial. A commercial product could simplify the overall treatment kit, but that would create combination-product and labeling issues.

What is the most defensible commercial positioning for a new cidofovir product?

The strongest positioning is a pharmacy-ready, preservative-free, stability-optimized infusion product that reduces preparation steps, controls container interactions, and supports predictable dosing without asserting unproven renal protection.

References

1. U.S. Food and Drug Administration. (1996). VISTIDE (cidofovir injection) prescribing information. Gilead Sciences, Inc.

2. U.S. Food and Drug Administration. (2023). Cidofovir: Clinical pharmacology and prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.

6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.